Thu07182019

Robins Global News & Noticias



  • Gaming Chair Review
    Gaming Chair Review
  • Data Recovery Review
    Data Recovery Review
  • Online Video Editors
    Online Video Editors
  • Download TV Series
    Download TV Series
  • All Elite Wrestling
    All Elite Wrestling
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: Forty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma at 24th Congress of the European Hematology Association


MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that updated data from its ongoing Phase 1b/2 clinical trial evaluating 5F9 in combination with rituximab for the treatment of relapsed/refractory non-Hodgkin’s lymphoma (r/r NHL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), will be presented in an oral presentation at the 24th Congress of the European Hematology Association (EHA) in Amsterdam, Netherlands, June 13-16, 2019.
In an additional oral presentation, Forty Seven will present initial data from its Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These data in AML and MDS will have been previously presented in a poster session on Monday, June 3, 2019 at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.Details on the presentations are as follows:Presentation Title: The first-in-class anti-CD47 antibody HU5F9-G4 with rituximab induces durable responses in relapsed/refractory DLBCL and indolent lymphoma: interim phase 1b/2 results
Oral Session Title: Aggressive Lymphomas – New Agents
Presentation Date & Time: Saturday, June 15, 2019 from 16:15-16:30 CEST (10:15 a.m. – 10:30 a.m. ET)
Abstract Code: S867
Location: Hall 5
Presentation Title: The first-in-class anti-CD47 antibody HU5F9-G4 is active and well tolerated alone or in combination with azacitidine in AML and MDS patients: initial phase 1b results
Oral Session Title: New Therapies in AML
Presentation Date & Time: Saturday, June 15, 2019 from 16:30-16:45 CEST (10:30 a.m. – 10:45 a.m. ET)
Abstract Code: S878
Location: Elicium 2
The accepted abstracts are now available online on the EHA website: https://ehaweb.org/congress/eha24/key-information/.About Forty Seven Inc.:
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developin...


Posted: 2019-05-16 13:01:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.


Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: Forty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma at 24th Congress of the European Hematology Association | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

BeiGene, Ltd. (BGNE)

Mon, 17 Jun 2019 23:37:00 GMT

in Chinese patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) in a poster at the 24th EHA Congress. A copy of the press release is filed as Exhibit 99.3 to this Current Report on ...

BeiGene Announces Clinical Results from Three Posters on Zanubrutinib Presented at the 24th Congress of European Hematology Association (EHA)

Fri, 14 Jun 2019 12:44:00 GMT

This exploratory analysis included five patients with treatment-naïve (TN) disease and 21 patients with relapsed/refractory (R/R ... including collectively 682 patients with non-Hodgkin’s lymphoma ...

BeiGene Announces Acceptance of New Drug Application for Anti-PD-1 Antibody Tislelizumab in Hodgkin’s Lymphoma in China

Fri, 31 Aug 2018 03:16:00 GMT

All other lymphomas are classified as non-Hodgkin’s lymphomas. Classical Hodgkin’s lymphoma, the most common form representing about 95 percent of the patients with Hodgkin’s lymphoma, is ...

Celgene’s Revlimid gets a win in late-stage lymphoma

Tue, 24 Jul 2018 03:37:00 GMT

Celgene has new phase III data that could add yet another string to blockbuster Revlimid’s bow – as a treatment for patients with non-Hodgkin’s lymphoma ... Revlimid lymphoma trials – MAGNIFY pairing ...

BeiGene Announces Preliminary Topline Results of Pivotal Trial in China for Anti-PD-1 Antibody Tislelizumab in Hodgkin’s Lymphoma

Sun, 22 Jul 2018 13:44:00 GMT

in Chinese patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL). “We are excited to announce the preliminary topline results from our first pivotal trial for tislelizumab. Despite ...

Related Twitter Search

  • No items found
  • Related News Story Videos From Youtube

    MABCUTE: rituximab maintenance in R/R indolent NHL


    Related Videos On: MABCUTE: rituximab maintenance in R/R indolent NHL


    JULIET: CRS and neurotoxicity in DLBCL


    Related Videos On: JULIET: CRS and neurotoxicity in DLBCL


    Primary mediastinal large b-cell lymphoma (PMBL): Helen's story


    Related Videos On: Primary mediastinal large b-cell lymphoma (PMBL): Helen's story


    First-line therapy in FL & CLL


    Related Videos On: First-line therapy in FL & CLL


    Idelalisib for Previously Treated CLL


    Related Videos On: Idelalisib for Previously Treated CLL






    Blow Us A Whistle

    Comments (Whistles) Designed By Disqus




    Company Information

    Official Content Providers











    PRIVACY POLICY

    We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
    © 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
    RobinsPost provides links to news sites based on their RSS feeds.
    All trademarks, copyrights, videos, photos and logos are owned by news sources.
    News stories, videos and live streams are from trusted sources:
    Bing News, Google News, Faroo News, NewsApi.org and YouTube Search Results.
    ROBINSPOST Is Proudly Made In America.
    Where Quality, Safety and Service Comes First.